Kineta is about to initiate Phase 1 clinical trials of its α9α10 nAChR antagonist KCP506 for the treatment of chronic neuropathic pain

Kineta, a clinical stage biotechnology company that develops novel therapies in oncology, neuroscience and biodefense, announced that it has received regulatory approval for the initiation of Phase 1 clinical trials of KCP506, a first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of chronic neuropathic pain.

α9α10 nAChR antagonists have demonstrated robust analgesic, anti-neuroinflammatory and neuroprotective effects across multiple preclinical chronic pain models.  KCP506 may potentially be an effective treatment for many types of chronic neuropathic pain including radiculopathy, chemotherapy-induced peripheral neuropathy and diabetic neuropathy.

Kineta is planning to initiate a double-blind, placebo-controlled Phase 1 clinical trial of KCP506 in Q4 2020. These trials will evaluate the safety, tolerability, and pharmacokinetics of KCP506 in healthy subjects.

Read the press release here.

Read more about Kineta here.